Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Popovian

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Health Economics and Outcomes Research|December 4, 2024
Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?Anne M Sydor, Esteban Rivera, Robert Popovian
Current Medical Research and Opinion|December 18, 2018
Sowing confusion in the field: the interchangeable use of biosimilar terminologyLaura McKinley, John M Kelton, Robert Popovian
Journal of the American Pharmacists Association : Japha|May 1, 2022
Accessibility of adult immunizations in pharmacies compared to physician offices in low-income communitiesRobert Popovian, Wayne Winegarden, Esteban Rivera, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2017
Drug tendering: drug supply and shortage implications for the uptake of biosimilarsGeorge Dranitsaris, Ira Jacobs, Carol Kirchhoff, et al.
Pharmacoeconomics|June 30, 2017
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisSteven Simoens, Ira Jacobs, Robert Popovian, et al.
Cancer Management and Research|June 16, 2017
Can biosimilars help achieve the goals of US health care reform?Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
The Oncologist|May 18, 2018
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and TrustEduardo Cazap, Ira Jacobs, Ali McBride, et al.
The Annals of Pharmacotherapy|February 9, 2017
Biosimilars: Practical Considerations for PharmacistsJames G Stevenson, Robert Popovian, Ira Jacobs, et al.
Journal of Health Economics and Outcomes Research|March 28, 2024
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?Anne M Sydor, Emily Bergin, Jonathan Kay, et al.
Therapeutic Innovation & Regulatory Science|September 3, 2022
The Relative Contributions of NIH and Private Sector Funding to the Approval of New BiopharmaceuticalsDuane Schulthess, Harry P Bowen, Robert Popovian, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Health Economics and Outcomes Research|December 4, 2024
Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?Anne M Sydor, Esteban Rivera, Robert Popovian
Current Medical Research and Opinion|December 18, 2018
Sowing confusion in the field: the interchangeable use of biosimilar terminologyLaura McKinley, John M Kelton, Robert Popovian
Journal of the American Pharmacists Association : Japha|May 1, 2022
Accessibility of adult immunizations in pharmacies compared to physician offices in low-income communitiesRobert Popovian, Wayne Winegarden, Esteban Rivera, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2017
Drug tendering: drug supply and shortage implications for the uptake of biosimilarsGeorge Dranitsaris, Ira Jacobs, Carol Kirchhoff, et al.
Pharmacoeconomics|June 30, 2017
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisSteven Simoens, Ira Jacobs, Robert Popovian, et al.
Cancer Management and Research|June 16, 2017
Can biosimilars help achieve the goals of US health care reform?Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
The Oncologist|May 18, 2018
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and TrustEduardo Cazap, Ira Jacobs, Ali McBride, et al.
The Annals of Pharmacotherapy|February 9, 2017
Biosimilars: Practical Considerations for PharmacistsJames G Stevenson, Robert Popovian, Ira Jacobs, et al.
Journal of Health Economics and Outcomes Research|March 28, 2024
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?Anne M Sydor, Emily Bergin, Jonathan Kay, et al.
Therapeutic Innovation & Regulatory Science|September 3, 2022
The Relative Contributions of NIH and Private Sector Funding to the Approval of New BiopharmaceuticalsDuane Schulthess, Harry P Bowen, Robert Popovian, et al.
Pageof 2